takeaways
- Doseology hired McKinney RSA to guide PMTA strategy, required testing, and compliance for oral pouch products.
- Scope includes nicotine and nicotine-analog formulations, plus labeling/claims and regulatory engagement planning.
- Doseology framed the partnership as a step toward regulatory compliance and commercial readiness.
Doseology Sciences Inc. said it has entered a strategic partnership with McKinney Regulatory Science Advisors, a U.S. Food and Drug Administration-focused regulatory consulting firm, to support Doseology’s regulatory submission strategy for its oral pouch technology platform.
Doseology said McKinney will advise on formulation strategy, data generation, PMTA preparation, and post-market compliance, with the stated goal of positioning the company for commercialization in regulated markets.
“Doseology is committed to leading with science and innovation in the oral pouch category,” said Tim Corkum, president & COO of Doseology, adding that the engagement is intended to align product development with regulatory expectations and to support “a defensible, regulatory-ready platform that prioritizes dose consistency and consumer safety.”
McKinney CEO Willie McKinney said his firm looks forward to supporting the advancement of Doseology’s product portfolio, citing regulatory science work to “identify, characterize, and manage product risks.”
Doseology said the engagement will include regulatory landscape assessments for stimulant, nicotine, and nicotine-alternative pouch formats; defining testing requirements to support anticipated submissions; advising on labeling and claims language; building a pre-submission engagement plan with regulators; and recommending post-market surveillance and adverse event reporting processes.
